DUSP22 Inhibitors

BML-260 acts as a selective DUSP22 inhibitor, exhibiting unique binding characteristics that disrupt the enzyme's phosphatase activity. Its molecular design facilitates specific interactions with the active site, altering the enzyme's conformation and hindering substrate access. This compound influences signaling pathways by modulating the dephosphorylation of key proteins, thereby affecting cellular responses and regulatory networks. Its kinetic profile reveals a distinct competitive inhibition mechanism, underscoring its role in fine-tuning cellular signaling dynamics.

NSC-95397 acts as an inhibitor of DUSP22 by binding to its active site. By doing so, it disrupts the enzyme's ability to dephosphorylate its substrate proteins, including critical signaling molecules like ERK and JNK. This interference results in prolonged phosphorylation and activation of downstream signaling pathways.

SP600125 inhibits DUSP22 by disrupting its dephosphorylation activity towards JNK and other substrates. This results in the prolonged activation of JNK and downstream signaling events that impact cellular functions, including cell proliferation and apoptosis.

FR180204 is a chemical inhibitor of DUSP22. It operates by inhibiting the dephosphorylation activity of DUSP22, thereby enhancing the phosphorylation and activation of MAP kinases. This modulation of MAP kinase signaling pathways affects various cellular processes.

SB203580 inhibits DUSP22 indirectly by blocking p38 MAP kinase, a substrate of DUSP22. By doing so, it prevents p38 MAP kinase inactivation, leading to altered cellular responses mediated by p38 MAP kinase signaling.

VX-745 is a small molecule inhibitor of DUSP22 and JNK. It interferes with the dephosphorylation activity of DUSP22 on JNK, leading to prolonged JNK activation and subsequent changes in cellular processes influenced by JNK signaling pathways.

BIRB 796 is an inhibitor that targets DUSP22 and other kinases. It inhibits DUSP22's dephosphorylation activity on MAP kinases, resulting in sustained kinase activation and modulation of cellular signaling pathways that impact cell fate and function.

PD 198306 is a chemical inhibitor that specifically targets DUSP22. It disrupts DUSP22′s ability to dephosphorylate its substrates, including ERK and JNK. This leads to prolonged phosphorylation and activation of MAP kinases and downstream cellular responses.

AS601245 inhibits DUSP22 by interfering with its dephosphorylation activity towards p38 MAP kinase and other substrates. This leads to sustained activation of p38 MAP kinase and downstream signaling events that influence cellular functions.

SB202190 is an inhibitor that indirectly affects DUSP22 by inhibiting p38 MAP kinase, a substrate of DUSP22. By preventing p38 MAP kinase inactivation, it alters cellular responses mediated by p38 MAP kinase signaling pathways.